Meisner Lara's Form 4 filing
Viridian Therapeutics, Inc. (VRDN) · filed Dec 22, 2022
- Accession no.
- 0000899243-22-039217
- Filed
- Dec 22, 2022
- Trade date
- Dec 20-21, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $493.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meisner LaraCIK 0001883986 | Officer (General Counsel and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2022 | Common Stock | MOption exerciseAcquired | +600 | $23.03 | +$13,818 | 600 | Direct | |
| Dec 20, 2022 | Common Stock | SSaleDisposed | −600 | $28.07 | −$16,842 | 0 | Direct | |
| Dec 21, 2022 | Common Stock | MOption exerciseAcquired | +16,326 | $23.03 | +$375,987.78 | 16,326 | Direct | |
| Dec 21, 2022 | Common Stock | SSaleDisposed | −16,326 | $29.19 | −$476,555.94 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 20, 2022 | Common Stock | MOption exerciseDisposed | −600 | $0.00 | $0 | 61,047 | Direct | |
| Dec 21, 2022 | Common Stock | MOption exerciseDisposed | −16,326 | $0.00 | $0 | 44,721 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.